Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Submit a comment

A subpopulation of normal human peripheral B lymphcytes that bind IgE.
A Gonzalez-Molina, H L Spiegelberg
A Gonzalez-Molina, H L Spiegelberg
Published April 1, 1977
Citation Information: J Clin Invest. 1977;59(4):616-624. https://doi.org/10.1172/JCI108679.
View: Text | PDF
Research Article

A subpopulation of normal human peripheral B lymphcytes that bind IgE.

  • Text
  • PDF
Abstract

Isolated normal human peripheral lymphocytes were analyzed for their ability to bind IgE as shown by rosette formation with aldehydefixed ox red cells coated with an IgE myeloma protein (Eo'-IgE) as indicator cells. An average of 4.3% of the cells in the lymphocyte preparations of 12 donors formed Eo'-IgE rosettes. The lymphocyte preparations contained an average of 0.36% basophils which also formed Eo'-IgE' rosettes, suggestiing that about 4% of the lymphocytes bound IgE. The rosette formation was inhibited by IgE myeloma protiens or IgE Fc fragments but not by IgE Fab fragments or Ig of the other classes. On the average, the lymphocytes of the 12 donors contained 70.5% cells forming spontaneous rosettes with sheep erythrocytes (E), 10.6% cells having surface immunoglobulin (SIg), and 15.5% bunding IgG as shown by rosette formation with IgG-coated ox red cells (EoA). Fractionation of the lymphocytes into populations rich in spontaneously E-rosetting cells and cells with SIg indicated that the majority of the lymphocytes forming Eo'-IgE rosettes belonged to the SIg-positive lymphocytes. Analyses of lymphocyte populations lacking cells forming EoA rosettes and of rosetting with mixed indicator cells both demonstrated that over 90% of the lymphocytes forming Eo'-IgE rosettes did not form EoA rosettes and apparently had no Fc receptors for IgG. Pretreatment of the lymphocytes with trypsin in amounts that did not alter the number of EoA-rosetting cells abolished the Eo'-IgE rosette formation. These data indicate that a subpopulation of normal human peripheral lymphocytes, probably belonging to the B-cell type, binds IgE presumably via trypsin-sensitive receptors specific for the Fc fragment of IgE. The surface markers of these lymphocytes resemble those of cultured human lymphoblastoid cells that have recently been shown to bind IgE.

Authors

A Gonzalez-Molina, H L Spiegelberg

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts